Generic peptide drugs: how to verify FDA approval in the Orange Book

01

Generic is a product-specific FDA approval category

FDA-approved generic medicines must meet the agency’s requirements for the same active ingredient, strength, dosage form, route of administration, quality, performance, and intended use as the reference product, with certain permitted differences. FDA also evaluates bioequivalence and manufacturing information before approval.

Those requirements apply to the specific finished product in the approved application. A seller cannot establish generic status by using the same ingredient name, pointing to an NDC number, or saying its formulation is similar to a brand. The application number and FDA product record are central.

Peptide chemistry can make development and characterization complex, but the consumer verification task remains concrete: find the exact approved product and compare its regulatory record. FDA’s 2025 first-generic list, for example, includes liraglutide injection referencing Saxenda, showing that peptide-related products can have approved generic competition.

02

Search the Orange Book in two passes

FDA recommends beginning with the proprietary, or brand, name to identify the active ingredient. Then search the ingredient to display approved products grouped by dosage form and route. This two-pass method helps prevent a match to the wrong formulation.

Within a dosage-form and route grouping, identify the Reference Listed Drug, or RLD. When approved products from other applicants exist, review the Therapeutic Equivalence, or TE, code. FDA’s Orange Book FAQ explains that products with matching applicable TE codes within the same grouping are evaluated for therapeutic equivalence.

Record the application number, applicant, product number, strength, route, marketing status, RLD field, and TE code. If the marketed name or label cannot be matched to the record, ask the pharmacy for the manufacturer and application details rather than guessing.

• →Search the brand name.
• →Confirm the active ingredient.
• →Search the ingredient.
• →Match dosage form, route, and strength.
• →Compare the RLD and TE-code fields.
• →Open the application and current label in Drugs@FDA.

03

What therapeutic equivalence does—and does not—mean

FDA describes therapeutic equivalents as approved products that are pharmaceutical equivalents, have demonstrated bioequivalence, are adequately labeled, and meet manufacturing requirements. The determination is not a ranking among products and does not mean two different active ingredients used for the same condition are interchangeable.

TE codes must be read within the relevant heading and grouping. A route, dosage-form, strength, or reference-product difference can change the comparison. Similar ingredient names alone are not enough, and one approved presentation does not automatically establish equivalence for another.

Therapeutic equivalence also does not decide which product is appropriate for an individual. Substitution questions depend on the exact prescription, product, labeling, and applicable state law and should be discussed with the pharmacist and prescriber.

04

Orange Book, Purple Book, and Drugs@FDA have different roles

The Orange Book covers approved drug products under the Federal Food, Drug, and Cosmetic Act and provides therapeutic-equivalence, patent, and exclusivity information. Drugs@FDA provides application-level records, labels, approval letters, and reviews for approved brand and generic drugs and many therapeutic biological products.

The Purple Book contains FDA-licensed biological products, including reference products, biosimilars, and interchangeable biosimilars. Generic and biosimilar are not interchangeable terms. If the product was approved under a biologics license application, use the Purple Book and biologics terminology.

Some products that people broadly call peptides may be regulated through different application pathways. Do not decide which database to use from marketing language alone. Start in Drugs@FDA, identify whether the record is an NDA, ANDA, or BLA, and then use the corresponding Orange Book or Purple Book details.

05

A compounded peptide is not a generic peptide drug

FDA states directly that compounded drugs and generic drugs are not the same. An approved generic has an ANDA and meets the requirements of section 505(j), including therapeutic-equivalence requirements. A compounded drug is not FDA-approved and does not undergo that premarket review.

Advertising phrases such as generic semaglutide, generic tirzepatide, or generic peptide can therefore be misleading when the product is compounded. Ingredient similarity, a lower price, a pharmacy license, or 503A or 503B status does not create generic approval.

Ask whether the pharmacy is dispensing an FDA-approved product from a named manufacturer or preparing a compounded product. The label should identify the dispensing or manufacturing entity. Verify the approved product in the Orange Book rather than relying on the clinic’s shorthand.

06

How to document a defensible product check

Save the official Orange Book or Purple Book result, the Drugs@FDA application page, and the current label. Record the exact product name, ingredient, dosage form, route, strength, applicant, application type and number, marketing status, and date checked. Repeat the search if the pharmacy, label, or presentation changes.

FDA notes that approval and market availability are distinct. A product can appear in an approval list without being available from a manufacturer or pharmacy on that date. Do not turn an approval record into a guarantee of stock, price, insurance coverage, or suitability.

If a clinic’s generic claim cannot be matched, request clarification in writing. Do not use a directory article to substitute one product for another or change treatment. Product selection and substitution questions belong with an appropriately licensed prescriber and pharmacist.